The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

humedics.de

Founded Year

2010

Stage

Series C | Alive

Total Raised

$8.44M

Last Raised

$7.82M | 8 yrs ago

About Humedics

Humedics has developed a breath test based diagnostic system (LiMAx test), which comprises a CE-marked medical device, breath masks and a diagnostic drug. More than 100 million people world-wide suffer from liver diseases (i.e. cirrhosis, hepatitis, fatty liver, metabolic disorders and liver tumors). The LiMAx test enables the clinician to quantitatively determine the individual liver function capacity for a patient within minutes. This allows for selection of treatment strategies that are optimally adapted to the individual patients liver status. Current applications include diagnosis of the liver function before and after liver transplantation, liver surgery planning (e.g. assessment of the amount of liver to be resected without potentially increasing the risk of liver failure) and assessment of diseases such as liver cirrhosis. The LiMAx test has been used more than 12,500 times in clinical practice. Results have been published in highly respected scientific journals. For the approval of the LiMAx test Humedics is presently conducting a phase III multi-center clinical trial.

Humedics Headquarter Location

Marie-Elisabeth-Lüders Str. 1

Berlin, D-10625,

Germany

+49 30 590083240

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Humedics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Humedics is included in 2 Expert Collections, including Cancer.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

H

Health Monitoring & Diagnostics

3,095 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

Humedics Patents

Humedics has filed 6 patents.

The 3 most popular patent topics include:

  • Laser science
  • Optical devices
  • Semiconductor lasers
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/19/2017

12/8/2020

Spectroscopy, Laser science, Semiconductor lasers, Sensors, Optical devices

Grant

Application Date

5/19/2017

Grant Date

12/8/2020

Title

Related Topics

Spectroscopy, Laser science, Semiconductor lasers, Sensors, Optical devices

Status

Grant

Latest Humedics News

Reimbursement for the LiMAx® test: MEL Commission includes Humedics GmbH's LiMAx® test in the MEL list 2022

May 10, 2022

News provided by Humedics GmbH on Tuesday 10th May 2022 Reimbursement for the LiMAx® test in Austria New service group APG07.02 - "Special diagnostics - Gastrointestinal tract 2". New service HL 510 Liver function testwith application of a C13-labeled substrate (LE=per session) Reimbursement in outpatient setting with 458 points Berlin, 2022/05/09 - The MEL Commission of the Austrian Ministry of Social Affairs has included the LiMAx® test in the MEL list 2022. In the new service catalog, the new group "APG07.02 - Special diagnostics - Gastrointestinal tract 2" was created. Under APG07.02 A, the new service "HL510 - Liver function test with application of a C13-labeled substrate (LE=per session)" is listed - the LiMAx® test, the use of which can be coded with 458 points in an outpatient setting. The listing was based to a large extent on the results of the Mini Health Technology Assessment conducted in 2019 by the Competence Center for Medical Devices (CCMD). At the time, the institute confirmed the clinical and economic advantage of the LiMAx® system for interventional use in liver surgery and highlighted the non-invasive breath test as particularly innovative. With the help of the worldwide unique Liver Maximum Capacity Test (LiMAx®), which quantifies the maximum functional capacity of the liver, physicians can specifically examine the liver for possible diseases. The results can be used to better plan interventions on the liver and thus minimize risks for patients. "The inclusion on the MEL list confirms our assessment of the LiMAx®test in terms of the validity of our clinical data and its relevance for healthcare. This will now result in our unique diagnostic method, which measures the functional capacity of the liver in real time, not only helping patients and physicians alike, but also generating significant economic benefits for the healthcare system in Austria," assesses Ralf Kohnen, CBO of Humedics GmbH. Liver disease leads to approximately two million deaths per year worldwide. Current diagnostic tools often prove to be of limited applicability for the accurate measurement of liver function or for the prediction of various liver-related pathologies. A novel way of determining global liver function is the LiMAx® (maximum liver function capacity) test, which measures, in exhaled breath, the effectiveness of the liver to metabolize an intravenously administered solution (13C-methacetin). For numerous diseases, such as malignant liver tumors, the resection of segments of the liver is necessary. In surgical management, the use of the LiMAx®system leads to safer procedures and a reduction in postoperative intensive care unit days as well as days in hospital. The LiMAx® test is the first and only breath test in liver diagnostics to be included in the MEL list. In addition to convincing clinical data, the economic cost-benefit analysis has confirmed the cost-effectiveness of the LiMAx® system for use in surgery management and this led to its reimbursement. For more information about Humedics and the LiMAx® test, visit: www.humedics.eu or contact Kajo Wiest, Tel. +49-(0)30-62939550, kajo.wiest@humedics.de Press release distributed by Pressat on behalf of Humedics GmbH, on Tuesday 10 May, 2022. For more information subscribe and follow https://pressat.co.uk/

  • When was Humedics founded?

    Humedics was founded in 2010.

  • Where is Humedics's headquarters?

    Humedics's headquarters is located at Marie-Elisabeth-Lüders Str. 1, Berlin.

  • What is Humedics's latest funding round?

    Humedics's latest funding round is Series C.

  • How much did Humedics raise?

    Humedics raised a total of $8.44M.

  • Who are the investors of Humedics?

    Investors of Humedics include High-Tech Grunderfonds, Peppermint VenturePartners, IBB Beteiligungsgesellschaft, Seventure Partners, ERP-Startfonds and 5 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.